Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease

	Tweet

A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the Sept. 20 Journal of Clinical Oncology.

“Men with prostate cancer have high five-year survival rates, but they also have higher rates of non-cancer mortality than healthy men,” says study author Nancy Keating, MD, MPH, assistant professor of health care policy and of medicine at Harvard Medical School. “This study shows that a common hormonal treatment for prostate cancer may put men at significant risk for other serious diseases. Patients and physicians need to be aware of the elevated risk as they make treatment decisions.”

The principal systemic therapy for prostate cancer involves blocking testosterone production. This is done either by removal of the testes (bilateral orchiectomy), or more commonly, by regular injections of a gonadotropin-releasing hormone (GnRH) agonist drug. GnRH agonists are the main therapy for metastatic prostate cancer and may also improve survival for some men with locally-advanced cancers.

However, little is known about the efficacy of GnRH agonists in treating men with less-advanced local or regional prostate cancer, many of whom receive this therapy. Earlier studies have found GnRH agonists to be associated with obesity and insulin resistance, a precursor to diabetes.

“Our study found that men with local or regional prostate cancer receiving a GnRH agonist had a 44 percent higher risk of developing diabetes and a 16 percent higher risk of developing coronary heart disease than men who were not receiving hormone therapy,” says Keating, who is also a physician at Brigham and Women’s Hospital.

“Doctors should think twice about prescribing GnRH agonists in situations for which studies have not demonstrated improved survival until we better understand the risks of treatment,” says co-author Matthew Smith, MD, PhD, associate professor of medicine at HMS and a medical oncologist at Massachusetts General Hospital. “For men who do require this treatment, physicians may want to talk with their patients about strategies, such as exercise and weight loss, which may help to lower risk of diabetes and heart disease.”

Given the number of men receiving GnRH agonists, often for many months or years, these increased risks can have important implications for the health of prostate cancer survivors, says Keating. Additional studies are needed to fully understand the biological mechanisms responsible for these increased risks.

Prostate cancer is the most frequently diagnosed cancer among men, affecting more than 200,000 men in the United States every year. With prostate cancer’s favorable prognosis, however, decisions about treatments are particularly important because adverse effects and complications of treatments may impact overall health and quality of life more than prostate cancer itself.

The study assessed whether androgen deprivation therapy was associated with an increased incidence of diabetes, coronary heart disease, myocardial infarction, or sudden cardiac death by examining data from approximately 73,000 men age 66 or older who were diagnosed with local or regional prostate cancer.

This work was supported by the Prostate Cancer Specialized Program of Research Excellence (SPORE) of the National Cancer Institute, one of the National Institutes of Health.

RELATED STORIES:
How Prostate Cancer Packs a Punch   On Sex After Prostate Surgery, Confusing Data   Annual Prostate Cancer Screening Test Appears to Save Lives   Advanced-Stage Prostate Cancer Patients Experience 20-Year Survival Rates With Surgery   Baldness drug could mask prostate cancer marker   New Targeted Therapy Effective in Treating Advanced Prostate Cancer   PSA retesting interval can be individualized   Common genetic prostate cancer variant identified   Diet May Reduce Risk of Prostate Cancer   Study backs prostate screening for high risk men   Louis Gossett Jr. fighting prostate cancer   Prostate cancer increases hip fracture risk by eight times in 50 to 65 year-olds   Age alone should not be used to determine whether to treat prostate cancer with hormones   Link Uncovered Between Benign Prostatic Hyperplasia, NSAIDs   Virus might be one cause of prostate cancer-study   Tissue spacers reduce risk of rectal injury for prostate cancer patients   Patients who refuse prostate cancer surgery have worse long-term survival   Scientists discover way to block growth of prostate cancer cells   Dramatic Outcomes in Prostate Cancer Study   Few well performed studies address management of lymph node positive prostate cancer   Prostate cancer anxiety may affect therapy choices   Brisk walking may help men with prostate cancer, UCSF study finds

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]